Piramal Primes Hospital Injectables Play Via Janssen Products
Executive Summary
Piramal is continuing on its acquisitive spree, snapping up a basket of injectable products from Janssen that are expected to give the diversified Indian group a foothold in the $20bn-plus global generic injectable hospital drugs market.
You may also be interested in...
Piramal Dreams Big, Wants To Be In Top Five India-Listed Pharma
Nandini Piramal, executive director of Piramal Enterprises, discusses how things have shaped the group's pharma business, its continuing appetite for acquisitions, efforts to de-risk the supply chain for key starting materials and the outsourcing "framework" deployed by industry.
Piramal Dreams Big, Wants To Be In Top Five India-Listed Pharma
Nandini Piramal, executive director, Piramal Enterprises, discusses how things have shaped in the group's pharma business, its continuing appetite for acquisitions, efforts to de-risk the supply chain for key starting materials and the outsourcing "framework" deployed by industry.
Piramal Eyes 20% Pharma Stake Sale
Piramal Enterprises, one of India’s biggest conglomerates, has said it is looking to sell up to a 20% stake in its Piramal Healthcare business to raise funds for spurring growth of the division through acquisitions.